Nargiza Parpieva

991 total citations · 1 hit paper
34 papers, 425 citations indexed

About

Nargiza Parpieva is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Nargiza Parpieva has authored 34 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Infectious Diseases, 17 papers in Epidemiology and 9 papers in Surgery. Recurrent topics in Nargiza Parpieva's work include Tuberculosis Research and Epidemiology (32 papers), Pneumocystis jirovecii pneumonia detection and treatment (9 papers) and Diagnosis and treatment of tuberculosis (8 papers). Nargiza Parpieva is often cited by papers focused on Tuberculosis Research and Epidemiology (32 papers), Pneumocystis jirovecii pneumonia detection and treatment (9 papers) and Diagnosis and treatment of tuberculosis (8 papers). Nargiza Parpieva collaborates with scholars based in Uzbekistan, United Kingdom and Denmark. Nargiza Parpieva's co-authors include Philipp du Cros, Zinaida Tigay, Irina Liverko, Catherine Berry, Melvin Spigelman, Matthew Dodd, Emil Kazounis, Koert Ritmeijer, Ilaria Motta and Ronelle Moodliar and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Nargiza Parpieva

31 papers receiving 411 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

2022 154 citations Bern-Thomas Nyang’wa, Catherine Berry et al. profile →

Peers

Countries citing papers authored by Nargiza Parpieva

Since Specialization

Citations

This map shows the geographic impact of Nargiza Parpieva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nargiza Parpieva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nargiza Parpieva more than expected).

Fields of papers citing papers by Nargiza Parpieva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nargiza Parpieva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nargiza Parpieva. The network helps show where Nargiza Parpieva may publish in the future.

Co-authorship network of co-authors of Nargiza Parpieva

This figure shows the co-authorship network connecting the top 25 collaborators of Nargiza Parpieva. A scholar is included among the top collaborators of Nargiza Parpieva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nargiza Parpieva. Nargiza Parpieva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), Michael L. Rekart, (unknown), Gene L. Bidwell, (unknown), (unknown), Zinaida Tigay, Nargiza Parpieva, (unknown), (unknown), Diego E. Gómez, Andrew I. Mikhail, Animesh A. Sinha	2
2	How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial 2024 ·Antimicrobial Agents and Chemotherapy ·Ilaria Motta, (unknown), Andrew Ludman, Nathalie Lachenal, Matthew Dodd, (unknown), (unknown), (unknown), (unknown), (unknown), Irina Liverko, Nargiza Parpieva, Ronelle Moodliar, Varvara Solodovnikova, Emil Kazounis, Bern-Thomas Nyang’wa, Katherine Fielding, Catherine Berry	2
3	Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort 2024 ·PLOS Global Public Health ·(unknown), Tim Crocker-Buqué, Catherine Berry, (unknown), (unknown), Bern-Thomas Nyang’wa, Nargiza Parpieva, Irina Liverko, Varvara Solodovnikova, Animesh A. Sinha	1
4	Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018 2021 ·International Journal of Environmental Research and Public Health ·(unknown), Ajay Kumar, (unknown), (unknown), (unknown), (unknown), (unknown), Nargiza Parpieva	5
5	Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018 2021 ·International Journal of Environmental Research and Public Health ·(unknown), Yuliia Sereda, (unknown), (unknown), Nargiza Parpieva	0
6	Rapid Tuberculosis Diagnostics Including Molecular First- and Second-Line Resistance Testing Based on a Novel Microfluidic DNA Extraction Cartridge 2021 ·Journal of Molecular Diagnostics ·Markus Beutler, (unknown), (unknown), Sara Plesnik, (unknown), Martin Eckart, (unknown), (unknown), Bhagwan Maharjan, (unknown), Nargiza Parpieva, (unknown), (unknown), Sabine Hofmann-Thiel, (unknown), (unknown), Nils Paust, Harald Hoffmann	5
7	Risk Factors for Unfavorable Treatment Outcomes among the Human Immunodeficiency Virus-Associated Tuberculosis Population in Tashkent City, Uzbekistan: 2013–2017 2021 ·International Journal of Environmental Research and Public Health ·(unknown), (unknown), (unknown), Ana Ciobanu, (unknown), (unknown), (unknown), Nargiza Parpieva	6
8	Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018 2021 ·International Journal of Environmental Research and Public Health ·(unknown), Nargiza Parpieva, Irina Liverko, (unknown), Kostyantyn Dumchev, (unknown), (unknown), Anthony Harries	17
9	Adherence of drug-resistant tuberculosis patients to treatment in Tashkent, 2019-2020 2021 ·(unknown), Nargiza Parpieva, Irina Liverko, Hayk Davtyan, (unknown), (unknown)	0
10	Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan 2020 ·ERJ Open Research ·Philipp du Cros, (unknown), Zinaida Tigay, (unknown), Jane Greig, Graham Cooke, (unknown), (unknown), Catherine Berry, (unknown), D. Lister, Sebastian Dietrich, Cono Ariti, (unknown), Bern-Thomas Nyang’wa, Nargiza Parpieva, (unknown), Jay Achar	13
11	Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan 2020 ·PLoS ONE ·Shona Horter, Jay Achar, (unknown), Nargiza Parpieva, Zinaida Tigay, (unknown), Beverley Stringer	2
12	Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan 2020 ·BMC Infectious Diseases ·Shona Horter, Beverley Stringer, (unknown), Nargiza Parpieva, (unknown), Zinaida Tigay, (unknown), Jay Achar	13
13	Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia 2019 ·BMC Infectious Diseases ·A. Engström, (unknown), (unknown), (unknown), Katharina Kranzer, Matthias Merker, (unknown), Nargiza Parpieva, (unknown), Evgeni Sahalchyk, (unknown), Stefan Niemann, Harald Hoffmann	14
14	Surgical approach in multi- and extensively drug-resistant tuberculosis: resection and thoracomioplasty 2019 ·Electronic Journal of General Medicine ·(unknown), (unknown), Nargiza Parpieva, (unknown), (unknown)	1
15	Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study 2018 ·PLoS ONE ·Mathieu Bastard, Elisabeth Sánchez-Padilla, Philipp du Cros, (unknown), Nargiza Parpieva, (unknown), Արմեն Հայրապետյան, (unknown), (unknown), (unknown), (unknown), (unknown), Cathy Hewison, Francis Varaine, Maryline Bonnet	25
16	Recurrent tuberculosis and associated factors: A five - year countrywide study in Uzbekistan 2017 ·PLoS ONE ·(unknown), (unknown), Anthony Harries, Nargiza Parpieva, Katie Tayler‐Smith, Petros Isaakidis, Engy Ali, Sven Gudmund Hinderaker, (unknown), Andrew Ramsay, (unknown), Masoud Dara	17
17	Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan 2016 ·BMC Infectious Diseases ·Shona Horter, Beverley Stringer, Jane Greig, (unknown), (unknown), Nargiza Parpieva, Zinaida Tigay, Philipp du Cros	24
18	Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan 2016 ·BMC Medicine ·James M. Trauer, Jay Achar, Nargiza Parpieva, (unknown), Justin T. Denholm, Dennis Falzon, Ernesto Jaramillo, (unknown), Philipp du Cros, Emma S. McBryde	15
19	‘They prefer hidden treatment': anti-tuberculosis drug-taking practices and drug regulation in Karakalpakstan 2016 ·The International Journal of Tuberculosis and Lung Disease ·Beverley Stringer, Karen Lowton, (unknown), Nargiza Parpieva, (unknown), Philipp du Cros, Epco Hasker, (unknown)	8
20	Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study 2015 ·PLoS ONE ·(unknown), (unknown), (unknown), Katie Tayler‐Smith, Petros Isaakidis, Andrei Dadu, Pierpaolo de Colombani, Sven Gudmund Hinderaker, Nargiza Parpieva, (unknown), (unknown), (unknown), Engy Ali, Martin van den Boom, Asmus Hammerich, (unknown), Masoud Dara	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact